Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Short Interest Update

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) saw a significant increase in short interest during the month of July. As of July 31st, there was short interest totaling 8,827 shares, an increase of 68.7% from the July 15th total of 5,232 shares. Currently, 0.3% of the company’s shares are sold short. Based on an average trading volume of 4,750 shares, the days-to-cover ratio is presently 1.9 days.

Institutional Investors Weigh In On Invesco Biotechnology & Genome ETF

A number of institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada boosted its position in shares of Invesco Biotechnology & Genome ETF by 22.3% during the 1st quarter. Royal Bank of Canada now owns 75,402 shares of the company’s stock worth $4,783,000 after purchasing an additional 13,767 shares during the period. Goldman Sachs Group Inc. grew its position in Invesco Biotechnology & Genome ETF by 5.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 37,657 shares of the company’s stock valued at $2,389,000 after acquiring an additional 2,103 shares in the last quarter. Osaic Holdings Inc. increased its stake in Invesco Biotechnology & Genome ETF by 9.9% during the second quarter. Osaic Holdings Inc. now owns 9,441 shares of the company’s stock worth $605,000 after purchasing an additional 852 shares during the period. PNC Financial Services Group Inc. increased its stake in Invesco Biotechnology & Genome ETF by 74.5% during the third quarter. PNC Financial Services Group Inc. now owns 574 shares of the company’s stock worth $40,000 after purchasing an additional 245 shares during the period. Finally, Blair William & Co. IL lifted its position in shares of Invesco Biotechnology & Genome ETF by 150.0% during the third quarter. Blair William & Co. IL now owns 1,000 shares of the company’s stock worth $70,000 after purchasing an additional 600 shares in the last quarter.

Invesco Biotechnology & Genome ETF Stock Up 0.6%

NYSEARCA:PBE opened at $95.28 on Wednesday. Invesco Biotechnology & Genome ETF has a 52 week low of $67.41 and a 52 week high of $95.42. The stock’s fifty day moving average is $89.93 and its two-hundred day moving average is $83.93. The company has a market capitalization of $300.13 million, a P/E ratio of 20.44 and a beta of 0.70.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.